About the Event
Kineta is focused on improving outcomes for cancer patients by solving the problem of cancer resistance. Their novel drug programs are focused on addressing and correcting immunosuppression, low tumor immune response, and exhausted T cells.
- Initiating Phase 1 study in Q4 2022
- Partnerships in place with Genentech, Merck, and Fair Therapeutics
- They will become a NASDAQ listed company in late 2022
Their first drug targets non-small cell lung cancer, ovarian cancer, and colorectal cancer with a combined market opportunity of $48B.
Join our webinar to hear why Genentech, Wellcome Trust and the NIH have all chosen to partner with Kineta.